News | April 03, 2022
WHO suspends supply of Covaxin under Covax facility
WHO’s post EUA inspection found deficiencies in Good Manufacturing Practice at the facility
WHO’s post EUA inspection found deficiencies in Good Manufacturing Practice at the facility
Primarily set up to address the Covid-19 emergency, the WHO technology transfer hub has the potential to expand manufacturing capacity for other products as well, including treatments, and target other priorities such as malaria, HIV and cancer
U.S. NIAID-sponsored trial will evaluate heterologous booster regimens, including NVX-CoV2373, after primary series with current USFDA approved or emergency use authorized-vaccines
It is the fourth vaccine to get the nod for 12 years and older after Biological E’s Corbevax, Bharat Biotech’s Covaxin and Zydus Lifesciences Zy-CoV-D
Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships
To date, 30 crore vaccines have been produced as part of the commitment made to the Government of India
The DCGI has already approved Covovax for restricted use in emergency situations in adults on December 28th 2021
Paxlovid consists of nirmatrelvir, which inhibits a SARS-CoV-2 protein to stop the virus from replicating, and ritonavir, which slows down nirmatrelvir’s breakdown to help it remain in the body for a longer period at higher concentrations
Flowflex antigen test detects Covid-19, including the Omicron variant, in just 15 minutes with 98.8% accuracy
This is the ninth Covid-19 vaccine approved in India
Subscribe To Our Newsletter & Stay Updated
